BiotechTube

SHR1258

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancer

Conditions

Biliary Tract Cancer

Trial Timeline

Nov 1, 2020 → Jun 5, 2025

NCT ID
NCT04571710

About SHR1258

SHR1258 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Biliary Tract Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04571710. Target conditions include Biliary Tract Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04571710Phase 2Withdrawn

Competing Products

20 competing products in Biliary Tract Cancer

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
41
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
52
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
52
E6011 + PlaceboEisaiPhase 2
52
LenvatinibEisaiPhase 2
52
gemcitabine + cisplatinEli LillyPhase 2
52
gemcitabine + cisplatinEli LillyPhase 2
52
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
SHR-A1811Jiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
SHR-1210+GEMOXJiangsu Hengrui MedicinePhase 2
52
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
77
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
23
durvalumabAstraZenecaPhase 3
77
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabineAstraZenecaPhase 2/3
65
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + TremelimumabAstraZenecaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85